Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899687 | 0.93 | TRPV1 (0.36) | KMT2ALMNAL3MBTL1SMN1; SMN2TRPV1 | |
| SCHEMBL10006450 | 0.93 | TRPV1 (0.36) | KMT2ALMNAL3MBTL1SMN1; SMN2TRPV1 | |
| SCHEMBL10006332 | 0.92 | KMT2A (0.41) | KMT2ALMNAL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL10006326 | 0.91 | KMT2A (0.34) | KMT2ALMNAL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL10006393 | 0.90 | KMT2A (0.36) | KMT2ALMNAL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL10006489 | 0.89 | LMNA (0.37) | KMT2ALMNAL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL10006269 | 0.89 | KMT2A (0.36) | KMT2ALMNAL3MBTL1THRBSMN1; SMN2 | |
| SCHEMBL16749152 | 0.86 | FFAR2 (0.37) | AAK1 | |
| SCHEMBL10006447 | 0.86 | FFAR2 (0.37) | AAK1 | |
| SCHEMBL10006429 | 0.85 | CYP1A2 (0.38) | KMT2ALMNASMN1; SMN2TRPV1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649045-B1 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2649045-B1 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| EP-2649045-A2 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| WO-2012076466-A2 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | PC, ACACA, PCCA | KMT2A 3289/4885LMNA 456/4885L3MBTL1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.